BioStock: Spago takes Tumorad-01 study to the next level

Spago Nanomedical has increased the dose of its cancer drug candidate ¹⁷⁷Lu-SN201 in its phase I/IIa Tumorad-01 study, following a recommendation from the independent Data Monitoring Committee. The decision stems from data on six patients across two cohorts with five different cancer types, all showing a satisfactory safety profile. This step keeps Spago on course to complete the phase I part in 2025.

Read the article at biostock.se:

https://www.biostock.se/en/2025/03/spago-takes-tumorad-01-study-to-the-next-level/

This is a press release from BioStock - Connecting Innovation and Capital. https://www.biostock.se/en/